Gene therapy reduces HIV levels in small trials

September 20, 2011 by Deborah Braconnier report

(Medical Xpress) -- This weekend at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, Illinois, researchers from two different study groups, one on the east coast and one on the west coast, reported promising results from studies being conducted in gene therapy for the treatment of HIV.

In the last year, HIV patient Timothy Brown appeared to be cured from his HIV after receiving a from a patient who carried a mutated receptor known as CCR5 on the that the uses. These new studies are based on this case and the receptor CCR5.

The two studies included a total of 15 HIV-infected patients. The researcher removed T cells from the blood of the and modified them with an enzyme engineered by Sangamo BioSciences in California. This enzyme disables the CCR5 receptor. The patients were then infused with 10 billion modified cells.

The patients in the study were originally taking antiretroviral therapy when the study began. Within four weeks, six of the participants stopped taking their medication for a 12 week period. During this time, three of the patients saw a decrease in and one of the patient’s viral loads dropped to an undetectable level. This patient had an advantage at the beginning however. When it comes to genes, each person has two copies, one from the mother and one from the father. This patient already had one copied that carried a naturally occurring mutation. It is estimated that as many as five to 10 percent of HIV patients have a genetic form of this receptor already.

With an estimated 33 million people worldwide diagnosed with HIV, the hope of this research is to create what they call a “functional cure” for AIDS and reduce the need for antiretroviral therapy. More studies are needed to determine the level of gene modification that would provide a complete decrease in the HIV viral load. The goal is patients would still carry the virus but no longer need drugs to control it and prevent disease.

Related Stories

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.